✦ LIBER ✦

Phase II trials of 5-fluorouracil and leucovorin in patients with metastatic gastric or pancreatic carcinoma

✍ Scribed by Joseph Rubin; James G. Gallagher; Georgene Schroeder; Allan J. Schutt; Robert J. Dalton; John W. Kugler; Roscoe F. Morton; James A. Mailliard; Patrick A. Burch

Publisher: John Wiley and Sons
Year: 1996
Tongue: English
Weight: 384 KB
Volume: 78
Category: Article
ISSN: 0008-543X
DOI: 10.1002/(sici)1097-0142(19961101)78:9<1888::aid-cncr7>3.0.co;2-b

No coin nor oath required. For personal study only.

✦ Synopsis

Conducted as a collaborative trial of North Central Cancer Treatment Group and Mayo Clinic.

📜 SIMILAR VOLUMES

A phase II trial of 5-fluorouracil, doxo

A phase II trial of 5-fluorouracil, doxorubicin, mitomycin C, and leucovorin in advanced gastric carcinoma

✍ Susan G. Arbuck; Yusuf Silk Md; Harold O. Douglass Jr.; Hector Nava; Youcef M. R 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 363 KB 👁 2 views

To determine the feasibility and toxicity of combining leucovorin (CF) with a 5fluorouracil(5-FU) combination chemotherapy regimen currently accepted by many as standard treatment for gastric cancer, CF (500 mg/m') was administered in combination with the Georgetown S-FU, doxorubicin, and mitomycin

A phase II trial of 5-fluorouracil, leuc

A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma

✍ Pedro M. Sanz-Altamira; Karen Ferrante; Roger L. Jenkins; W. David Lewis; Mark S 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB 👁 1 views

## Background: Unresectable adenocarcinoma of the biliary tree are associated with a very poor prognosis. 5-fluorouracil (5-fu) combination regimens have produced objective response rates in approximately 10-20% of patients. leucovorin increases the selective cytotoxicity of 5-fu. there also are en

Phase II trial of gemcitabine and UFT mo

Phase II trial of gemcitabine and UFT modulated by leucovorin in patients with advanced pancreatic carcinoma

✍ J. Feliu; M. P. López Álvarez; M. A. Jaraiz; M. Constenla; J. M. Vicent; J. Beló 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB 👁 1 views

A comprehensive review of 5-fluorouracil

A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma

✍ David Machover 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB 👁 2 views

## Background: Colorectal carcinoma is the third leading cause of cancer-related death. the primary treatment for patients with metastatic colorectal carcinoma is systemic chemotherapy with 5-fluorouracil (5-fu) and leucovorin (lv), a biomodulator of 5-fu that has been shown to enhance its activity

Hypocalcemia associated with 5-fluoroura

Hypocalcemia associated with 5-fluorouracil and low dose leucovorin in patients with advanced colorectal or gastric carcinomas

✍ Yuichiro Kido; Takeshi Okamura; Morimasa Tomikawa; Manabu Yamamoto; Morio Shirai 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 367 KB 👁 2 views

## BACKGROUND. The biochemical modulation of 5-fluorouracil (5-FU) by leucovorin (Lv) has demonstrated significantly increased response rates in comparison with the use of 5-FU alone in patients with advanced colorectal carcinoma. However, the higher response rate of LV/5-FU may occur at the expen

Phase II study of oral eniluracil, 5-flu

Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma

✍ Neal J. Meropol; Donna Niedzwiecki; Donna Hollis; Richard L. Schilsky; Robert J. 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB 👁 2 views